✦ LIBER ✦

Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution

✍ Scribed by Lorenzo Falchi; Giovanna Rege-Cambrin; Carmen Fava; Emilio Donti; Debora Luzi; Emilia Giugliano; Marta Gubbiotti; Monica Schippa; Anna Marina Liberati

Book ID: 113513728
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 86 KB
Volume: 199
Category: Article
ISSN: 0165-4608
DOI: 10.1016/j.cancergencyto.2010.02.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival outcomes for clonal evolution i

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

✍ Dushyant Verma; Hagop Kantarjian; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guil 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Clonal chromosomal abnormalities in CD34

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

✍ Bumm, T; Deininger, J; Newell, A H; Lawce, H; Olson, S; Mauro, M; Druker, B; Dei 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 243 KB

The effect of interleukin 11 on thromboc

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Ahmed Aribi; Hagop Kantarjian; Charles Koller; Deborah Thomas; Stefan Faderl; Gu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

CD34+/Ph+ cells are still detectable in

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

✍ Bocchia, M; Ippoliti, M; Gozzetti, A; Abruzzese, E; Calabrese, S; Amabile, M; Pi 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 90 KB

The Achievement of a 3-Month Complete Cy

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

✍ Jabbour, Elias; Kantarjian, Hagop; Ghanem, Hady; O'Brien, Susan; Quintas-Cardama 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 305 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera